This federal Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) provides $423,447 in funding to Brown University to conduct research on the impact of social-contextual stressors on smoking cessation and relapse among socioeconomically disadvantaged young adults. The research aims to gain an in-depth understanding of how social-contextual stressors, such as financial stress, affect smoking cessation and relapse in this...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $395,995 to Oregon Health & Science University (OHSU) to conduct a longitudinal study examining the reciprocal relationships between cannabis use, sleep, and the hypothalamic-pituitary-adrenal (HPA) axis. The study will enroll 60 participants, including healthy controls and those with moderate and severe cannabis use disorder, to assess the...
This Project Grant award, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), is focused on identifying genes and molecular mechanisms that affect psychostimulant-induced sleep irregularities and sleep deprivation-caused changes in amphetamine preference. The $458,452 award will support research conducted by the University of Utah from June 1, 2025 to February 28, 2030. The project aims to: 1) determine the mechanisms of...
This Project Grant award, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund a mechanistic study to investigate how targeting the orexin system affects symptoms related to neurofunctional domains associated with opioid use disorder (OUD) and insomnia. The total award amount is $2,285,443 and the project period runs from September 30, 2024 to July 31, 2029. The study, led by Virginia Commonwealth University, will...
This Project Grant award of $443,263 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to characterize the unique effects of recreational cannabis use on sleep in women of childbearing age. The 5-year study, beginning September 2024, will examine the relationship between cannabis use and sleep, investigating the mediating role of stress physiology and reproductive hormones. The research will utilize a within-subject design...
This federal Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), provides $808,417 to Stony Brook University to conduct a mechanistic clinical trial evaluating the role of the metabotropic glutamate receptor subtype 5 (mGluR5) in the antidepressant mechanism of cognitive behavioral therapy for insomnia (CBT-I). The 5-year research project, starting on May 1, 2025, aims to determine if CBT-I can reduce mGluR5...
The federal Project Grant award R01MH133886 from the National Institute of Mental Health (CFDA 93.242 Mental Health Research Grants) provides $1,932,991 to Yale University to conduct research on the neural computations underlying learning, decision-making, and memory across reward and punishment domains. The 5-year study (Award Date: Aug 1, 2024 - Ultimate Completion Date: Mar 31, 2029) will involve behavioral testing of 1,000 participants and functional MRI scanning of 100 participants to...
This $1,432,724 federal Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), will fund a research study examining the developmental impacts of sleep patterns on positive valence systems and socioemotional functioning during pre-adolescence. The study consists of two components: 1) a one-year longitudinal burst design with a non-clinical sample of 290 youth aged 8-12 to assess behavioral and neurophysiological...
This Project Grant award of $1,704,286, awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), seeks to investigate the biological basis for why sleep apnea patients are more sensitive to opioid-induced respiratory depression (OIRD), a leading cause of opioid overdose deaths. The key objectives are to uncover how deficient oxytocin neurotransmission in the paraventricular nucleus of the hypothalamus contributes to OIRD...
This Project Grant award from the National Institute of Mental Health (NIMH, CFDA 93.242 Mental Health Research Grants) provides $588,018 to The Trustees of the University of Pennsylvania to investigate the neural basis of how stress impacts sleep architecture and cognition. The key focus is to determine how inputs from stress-regulatory neurons in the locus coeruleus and paraventricular nucleus of the hypothalamus disrupt specific features of sleep, such as microarousals and REM sleep...
This federal Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) provides $1,873,869 to Yale University to investigate the neural mechanisms connecting deficient sleep and smoking relapse. The project aims to examine how cognitive behavioral therapy for insomnia (CBT-I) can ameliorate negative emotions, improve self-control, and promote smoking cessation among adults who smoke. The research will identify neural markers of the effects of CBT-I, with a focus on dysfunction in the basal forebrain and hypothalamic circuits. The award period runs from Aug 1, 2024 to Jun 30, 2029.